Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3390/biomedicines2040275

http://scihub22266oqcxt.onion/10.3390/biomedicines2040275
suck pdf from google scholar
C5344275!5344275!28548072
unlimited free pdf from europmc28548072    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid28548072      Biomedicines 2014 ; 2 (4): 275-300
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • HGF?Met Pathway in Regeneration and Drug Discovery #MMPMID28548072
  • Matsumoto K; Funakoshi H; Takahashi H; Sakai K
  • Biomedicines 2014[Dec]; 2 (4): 275-300 PMID28548072show ga
  • Hepatocyte growth factor (HGF) is composed of an ?-chain and a ?-chain, and these chains contain four kringle domains and a serine protease-like structure, respectively. Activation of the HGF?Met pathway evokes dynamic biological responses that support morphogenesis (e.g., epithelial tubulogenesis), regeneration, and the survival of cells and tissues. Characterizations of conditional Met knockout mice have indicated that the HGF?Met pathway plays important roles in regeneration, protection, and homeostasis in various cells and tissues, which includes hepatocytes, renal tubular cells, and neurons. Preclinical studies designed to address the therapeutic significance of HGF have been performed on injury/disease models, including acute tissue injury, chronic fibrosis, and cardiovascular and neurodegenerative diseases. The promotion of cell growth, survival, migration, and morphogenesis that is associated with extracellular matrix proteolysis are the biological activities that underlie the therapeutic actions of HGF. Recombinant HGF protein and the expression vectors for HGF are biological drug candidates for the treatment of patients with diseases and injuries that are associated with impaired tissue function. The intravenous/systemic administration of recombinant HGF protein has been well tolerated in phase I/II clinical trials. The phase-I and phase-I/II clinical trials of the intrathecal administration of HGF protein for the treatment of patients with amyotrophic lateral sclerosis and spinal cord injury, respectively, are ongoing.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box